heart disease
-
Cardiol Furthers Clinical Trials to Advance Disruptive Cannabidiol-Based Therapies for Heart Disease
Heart disease continues to be a leading cause of death globally. According to Cardiol Therapeutics Inc. (NASDAQ: CRDL…
-
David Elsley of Cardiol Therapeutics talks about their global Phase II clinical trials for the treatment of heart diseases
In this InvestorIntel interview, Chris Thompson talks to Cardiol Therapeutics Inc.’s (NASDAQ: CRDL | TSX: CRDL) CEO, President and…
-
Hemostemix adds depth and strength to its scientific bench on the road to commercialization
Since we last covered Hemostemix where they released the promising results of their retrospective study of heart disease…
